Early Evidence Supporting KRAS G12C as a Druggable Target: High Response Rate for AMG 510 in Advanced NSCLC
Of the 23 patients with NSCLC who were evaluable for efficacy, the overall response rate was 48%, with a disease control rate of 96%.
Diagnosis & Disease Information
Microbiome Analysis May Be a Feasible Diagnostic Test for Prostate Cancer
The microbiome could have a role in the diagnosis of PrCa.
Patients With Metastatic NSCLC Characterized by LKB1 Mutations Found Less Likely to Benefit From First-Line Chemotherapy
In this study, LKB1 mutations without coexisting KRAS mutations were found in the tumor specimens of 13.6% of patients with metastatic NSCLC.
Integrative Analysis of Lung Cancer Etiology and Risk: An INTEGRAL Progress Report
One goal of the INTEGRAL initiative is to incorporate validated biomarkers of lung cancer risk into lung cancer CT screening protocols.
Germline Testing Should Be Routinely Conducted in Patients With Metastatic Breast Cancer
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
Recent Advances Offer Paths Forward for Developing Predictive Biomarkers in Cancer Immunotherapy
Recent advances in predictive biomarker development clarify how best to determine PD-L1 expression in tumor cells.
The Case for a 3-Tier Tumor Mutational Burden Classification Scheme to Identify Candidates for Immunotherapy
In many cancers, there are no standard cutoff points for what would be considered “TMB-low” or “TMB-high.”
Adjusting the Risk Calculation for Biopsy-Detectable Prostate Cancer
Researchers sought to demonstrate how recalibration of risk stratification tools can improve accuracy and clinical decision making.
Tumor-Initiating Cell Marker Identified in Myeloma
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
New Trial Attempts to Make Genetic Counseling and Testing More Accessible
The researchers wrote that “genetic counseling must be further explored to find an optimal balance of clinical quality with increased access and financial sustainability.”
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...